Regeneron Says European Commission Has Approved Ordspono To Treat Adult Patients With Relapsed Or Refractory Follicular Lymphoma Or R/R Diffuse Large B-cell Lymphoma, After Two Or More Lines Of Systemic Therapy
Portfolio Pulse from Benzinga Newsdesk
Regeneron has received approval from the European Commission for Ordspono, a bispecific antibody, to treat adult patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic therapy. This is the first regulatory approval for Ordspono globally, based on successful Phase 1 and Phase 2 trials.
August 26, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron has achieved a significant milestone with the European Commission's approval of Ordspono for treating certain types of lymphoma. This approval, based on successful clinical trials, marks the first global regulatory approval for Ordspono.
The approval of Ordspono by the European Commission is a major regulatory milestone for Regeneron, potentially opening up new revenue streams in the European market. The successful clinical trials underpinning this approval suggest strong efficacy, which could enhance Regeneron's reputation and market position in oncology.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90